Private Advisor Group LLC Makes New $443,000 Investment in Humana Inc. (NYSE:HUM)

Key Points

• Private Advisor Group LLC has acquired 1,674 shares of Humana Inc. (NYSE:HUM), valued at approximately $443,000, in the first quarter, indicating growing institutional interest in the stock.
• Humana's share price has seen a 13.9% increase, with current trading at around $264.97, and a market cap of $31.98 billion.
• Despite a revenue increase of 9.6% compared to last year, Humana reported a slight earnings miss in its latest quarterly results, with EPS of $6.27 versus an estimate of $6.32.

Private Advisor Group LLC purchased a new position in shares of Humana Inc. (NYSE:HUM - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,674 shares of the insurance provider's stock, valued at approximately $443,000.

Other large investors also recently bought and sold shares of the company. Riverview Trust Co purchased a new position in Humana during the 1st quarter worth approximately $34,000. Garde Capital Inc. purchased a new position in Humana during the 1st quarter worth approximately $36,000. Transce3nd LLC purchased a new position in Humana during the 4th quarter worth approximately $38,000. Whipplewood Advisors LLC grew its stake in Humana by 639.1% during the 1st quarter. Whipplewood Advisors LLC now owns 170 shares of the insurance provider's stock worth $45,000 after buying an additional 147 shares during the last quarter. Finally, Colonial Trust Advisors grew its stake in Humana by 4,500.0% during the 4th quarter. Colonial Trust Advisors now owns 184 shares of the insurance provider's stock worth $47,000 after buying an additional 180 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company's stock.

Analyst Ratings Changes

Several research analysts have weighed in on HUM shares. Oppenheimer lifted their target price on Humana from $300.00 to $310.00 and gave the company an "outperform" rating in a research note on Thursday, May 1st. Barclays set a $275.00 price target on Humana and gave the company an "equal weight" rating in a report on Thursday. Wall Street Zen raised Humana from a "hold" rating to a "buy" rating in a research note on Sunday, July 20th. Robert W. Baird dropped their price objective on Humana from $300.00 to $297.00 and set a "neutral" rating for the company in a research note on Friday, July 25th. Finally, Raymond James Financial raised Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price objective for the company in a research note on Thursday, May 1st. Sixteen analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, Humana presently has a consensus rating of "Hold" and an average price target of $281.62.

Humana Trading Down 1.1%

HUM stock traded down $2.68 during trading on Friday, reaching $247.19. 1,756,006 shares of the stock traded hands, compared to its average volume of 1,854,830. The business's 50 day moving average price is $235.09 and its 200-day moving average price is $255.24. Humana Inc. has a 52-week low of $206.87 and a 52-week high of $382.72. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.91. The firm has a market capitalization of $29.73 billion, a PE ratio of 18.97, a P/E/G ratio of 1.66 and a beta of 0.44.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). Humana had a net margin of 1.28% and a return on equity of 13.67%. The firm had revenue of $32.39 billion for the quarter, compared to analysts' expectations of $31.85 billion. During the same period last year, the firm posted $6.96 EPS. Humana's revenue was up 9.6% on a year-over-year basis. As a group, sell-side analysts forecast that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.